We demonstrate that inhibition of the ERK1/2 pathway with trametinib, along with the use of a TKI, such as midostaurin, could be a beneficial therapeutic strategy in patients with AML and mutated or non-mutated FLT3. This evidence concerns the gene MAPK3 and acute myeloid leukemia.